3.0 T MRI features of breast cancer in different molecular types

Share this content in WeChat

• CLINICAL ARTICLE •

CHEN Yongsheng SUN Shengjun YU Xiaojun WU Shasha NIU Qingliang

Cite this article as: Chen YS, Sun SJ, Yu XJ, et al. 3.0 T MRI features of breast cancer in different molecular types[J]. Chin J Magna Reson Imaging, 2021, 12(2): 24-28. DOI:10.12015/issn.1674-8034.2021.02.006.

Abstract

[Abstract] Objective To explore the MRI features of breast cancer indifferent molecular types. Materials andMethods MRI findings of 240 patients with breast cancer confirmed by operation or puncture pathology in our hospital were retrospectively analyzed. The MRI features of tumor size, shape, boundary, enhancement type, time signal intensity curve (TIC), background parenchymal enhancement (BPE), peritumoral edema, and presence of axillary enlarged lymph nodes were compared in different molecular subtypes of breast cancer. Statistical analysis was performed by chi square test of contingency table to analyze the MRI imaging features and correlation of breast cancer in different molecular types.Results There were statistically significant differences in the size (C=0.197, P=0.021), shape (C=0.247, P=0.015), enhancement type (C=0.251, P=0.012), type of TIC (C=0.253, P=0.011), and incidence of axillary enlarged lymph nodes (C=0.189, P=0.029) among different molecular subtypes of breast cancer. Luminal A subtype often presented as a round mass lesion ≤2 cm (70%). Luminal B subtype TIC curves were mostly type Ⅲ (81.3%). HER-2 subtypeaccounted for a higher proportion of non-mass type breast cancer (41.7%), and had a high incidence of axillary enlarged lymph nodes (50%). Round mass lesion (84%) and ring enhancement (64%) were more often found in triple negative breast cancers (TNBC). Peritumoral edema was found in 52% of TNBC and 45.8% of HER-2 subtypes, that was significantly higher than luminal A (18%) and luminal B (25%) (P＜0.01). There was no significant correlation between tumor boundary (C=0.195, P=0.141), BPE (C=0.158, P=0.720) and molecular subtypes.Conclusions Different molecular subtypes of breast cancer have certain characteristics on MRI. According to the MRI features of breast cancer, the molecular classification can be preliminarily predicted, which will facilitate subsequent treatment planning and prognosis assessment.

[Keywords] breast neoplasms；magnetic resonance imaging；molecular subtypes；immunohistochemitry

Contributor Information

CHEN Yongsheng¹ SUN Shengjun¹ YU Xiaojun² WU Shasha² NIU Qingliang^2*

¹ Department of Medical Imaging, Weifang Medical University, Weifang 261053, China

² Medical Imaging Center, Weifang TCM Hospital, Weifang 261041, China

Niu QL, E-mail: qingliangniu@126.com

Conflicts of interest None.

Publication Information

Received 2020-08-14

Accepted 2021-01-12

DOI: 10.12015/issn.1674-8034.2021.02.006

Text

References

Alcala-Corona SA, de Anda-Jauregui G, Espinal-Enriquez J, et al. Network modularity in breast cancer molecular subtypes[J]. Front Physiol, 2017, 8: 915. DOI: 10.3389/fphys.2017.00915.

Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic[J]. Nat Rev Clin Oncol, 2016, 13(4): 228-241. DOI: 10.1038/nrclinonc.2015.215.

Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690. DOI: 10.1038/nrclinonc.2016.66.

Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. Arch Pathol Lab Med, 2010, 134(6): 907-922. DOI: 10.1043/1543-2165-134.6.907.

Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2019, 30(7): 1181. DOI: 10.1093/annonc/mdy537.

Expert group of breast Professional Committee of Radiology branch of Chinese Medical Association. Expert consensus on breast MRI and diagnostic criteria[J]. Oncoradiology, 2017, 26(4): 241-249.

Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50. DOI: 10.1016/S1470-2045(17)30904-X.

Wu J, Sun X, Wang J, et al. Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: Model discovery and external validation[J]. J Magn Reson Imaging, 2017, 46(4): 1017-1027. DOI: 10.1002/jmri.25661.

Grimm LJ, Zhang J, Baker JA, et al. Relationships between MRI breast imaging-reporting and data system (BI-RADS) lexicon descriptors and breast cancer molecular subtypes: Internal enhancement is associated with luminal B subtype[J]. Breast J, 2017, 23(5): 579-582. DOI: 10.1111/tbj.12799.

Yuan C, Jin F, Guo X, et al. Correlation analysis of breast cancer DWI combined with DCE-MRI imaging features with molecular subtypes and prognostic factors[J]. J Med Syst, 2019, 43(4): 83. DOI: 10.1007/s10916-019-1197-5.

Bae MS, Seo M, Kim KG, et al. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes[J]. Acta Radiol, 2015, 56(3): 269-275. DOI: 10.1177/0284185114524197.

Wen J, Kang WY, Deng WM, et al. MR manifestation of different molecular subtypes of breast cancer[J]. Chin J Oncol Prev Treat, 2019, 11(3): 257-261. DOI: 10.3969/j.issn.1674-5671.2019.03.14.

Wang Q, Chang XD. Diagnostic value of 3.0 T MRI in triple negative breast cancer[J]. Chin J Magn Reson Imaging, 2015, 6(4): 283-288. DOI: 10.3969/j.issn.1674-8034.2015.04.008.

Wang ZP, Liu GH, Chen Y, et al. Correlation between multimodal MRI and molecular typing of breast cancer[J]. J Pract Med, 2018, 34(10): 1725-1729. DOI: 10.3969/j.issn.1006-5725.2018.10.037.

Hou ML, Liu PF, Shao ZZ, et al. Correlation between background parenchymal enhancement and menstrual condition on breast MRI[J]. J Clin Radiol, 2016, 35(3): 343-347. DOI: 10.13437/j.cnki.jcr.2016.03.009.

Kawashima H, Inokuchi M, Furukawa H, et al. Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects[J]. Springerplus, 2014, 3: 240. DOI: 10.1186/2193-1801-3-240.

Du LJ, Yang P. Correlation between imaging features and immunohistochemical results in breast cancer[J]. Oncoradiology, 2018, 27(3): 215-218. DOI: 10.19401/j.cnki.1007-3639.2018.03.017.

Navarro VL, Alandete GS, Medina GR, et al. MR imaging findings in molecular subtypes of breast cancer according to BIRADS system[J]. Breast J, 2017, 23(4): 421-428. DOI: 10.1111/tbj.12756.

Cheon H, Kim HJ, Kim TH, et al. Invasive breast cancer: Prognostic value of peritumoral edema identified at preoperative MR imaging[J]. Radiology, 2018, 287(1): 68-75. DOI: 10.1148/radiol.2017171157.

Wang TT, Zhou J, Tian N, et al. Correlation of mammography, MRI features and molecular typing of breast cancer[J]. Chin J Magn Reson Imaging, 2019, 10(6): 420-424. DOI: 10.12015/issn.1674-8034.2019.06.005.

Gangi A, Mirocha J, Leong T, et al. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases[J]. Ann Surg Oncol, 2014, 21(13): 4098-4103. DOI: 10.1245/s10434-014-3989-7.

Mazouni C, Rimareix F, Mathieu MC, et al. Outcome in breast molecular subtypes according to nodal status and surgical procedures[J]. Am J Surg, 2013, 205(6): 662-667. DOI: 10.1016/j.amjsurg.2012.06.006.

PREV The diagnostic value of IVIM in glioma grading and its correlation with Ki-67 labeling index

NEXT Radiomics features based on pharmacokinetic dynamic contrast-enhanced magnetic resonance imaging for identifying triple negative breast cancer

LINK

Tel & Fax: +8610-67113815 E-mail: editor@cjmri.cn